$544.55
0.45%
Nasdaq, Jul 07, 08:12 pm CET
ISIN
US45168D1046
Symbol
IDXX
Sector

IDEXX Laboratories Stock price

$547.01
+21.18 4.03% 1M
+131.48 31.64% 6M
+133.57 32.31% YTD
+69.52 14.56% 1Y
+188.57 52.61% 3Y
+212.25 63.40% 5Y
+484.61 776.62% 10Y
+531.50 3,426.82% 20Y
Nasdaq, Closing price Thu, Jul 03 2025
+4.30 0.79%
ISIN
US45168D1046
Symbol
IDXX
Sector

Key metrics

Basic
Market capitalization
$44.0b
Enterprise Value
$44.8b
Net debt
$776.3m
Cash
$164.0m
Shares outstanding
80.7m
Valuation (TTM | estimate)
P/E
50.1 | 44.1
P/S
11.2 | 10.4
EV/Sales
11.4 | 10.6
EV/FCF
53.4
P/B
30.5
Financial Health
Equity Ratio
48.4%
Return on Equity
55.7%
ROCE
55.2%
ROIC
32.7%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$3.9b | $4.2b
EBITDA
$1.3b | $1.5b
EBIT
$1.1b | $1.3b
Net Income
$895.0m | $1.0b
Free Cash Flow
$837.7m
Growth (TTM | estimate)
Revenue
5.6% | 8.3%
EBITDA
3.9% | 16.9%
EBIT
2.7% | -
Net Income
3.3% | 12.8%
Free Cash Flow
5.1%
Margin (TTM | estimate)
Gross
61.3%
EBITDA
32.6% | 35.0%
EBIT
29.1%
Net
22.8% | 23.7%
Free Cash Flow
21.3%
More
EPS
$10.9
FCF per Share
$10.4
Short interest
4.1%
Employees
11k
Rev per Employee
$350.0k
Show more

Create a Free Account to create an IDEXX Laboratories alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

IDEXX Laboratories Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a IDEXX Laboratories forecast:

13x Buy
65%
7x Hold
35%

Analyst Opinions

20 Analysts have issued a IDEXX Laboratories forecast:

Buy
65%
Hold
35%

Financial data from IDEXX Laboratories

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3,932 3,932
6% 6%
100%
- Direct Costs 1,523 1,523
3% 3%
39%
2,409 2,409
8% 8%
61%
- Selling and Administrative Expenses 1,037 1,037
12% 12%
26%
- Research and Development Expense 226 226
14% 14%
6%
1,280 1,280
4% 4%
33%
- Depreciation and Amortization 134 134
15% 15%
3%
EBIT (Operating Income) EBIT 1,146 1,146
3% 3%
29%
Net Profit 895 895
3% 3%
23%

In millions USD.

Don't miss a Thing! We will send you all news about IDEXX Laboratories directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEXX Laboratories Stock News

Neutral
Business Wire
13 days ago
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference cal...
Neutral
PRNewsWire
about one month ago
The Catalyst ® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome WESTBROOK, Maine , June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst® Cortisol Test, which measures real-time quantitative cortisol conce...
Neutral
Seeking Alpha
about 2 months ago
IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and m...
More IDEXX Laboratories News

Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Head office United States
CEO Jonathan Mazelsky
Employees 11,000
Founded 1983
Website www.idexx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today